Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Net Loss and Earnings per Diluted Share of $11.4 million and $0.80 Adjusted EBITDA was a $3.5 million loss, a $5.5 million improvement versus fourth quarter of 2022 The Company confirms it expects...
-
Austin, TX, USA, April 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cloud Based Financial Platform Market Size, Trends and Insights By Deployment...
-
Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Forian Inc. (Nasdaq: FORA), a provider of...
-
Dubái (Emiratos Árabes Unidos), March 28, 2024 (GLOBE NEWSWIRE) -- OKX, uno de los principales exchages de cripto y de las empresas tecnológicas de la Web3 más importantes a nivel mundial,...
-
Dubai, Emirados Árabes Unidos, March 28, 2024 (GLOBE NEWSWIRE) -- A OKX, uma empresa líder global em tecnologia Web3 e corretora de criptomoedas, anunciou hoje a publicação do seu relatório de...
-
دبي, March 28, 2024 (GLOBE NEWSWIRE) -- الإمأعلنت OKX، الشركة العالمية الرائدة في مجال تكنولوجيا Web3 ومنصة تداول العملات الرقمية، اليوم عن إصدار أحدث تقرير لها عن إثبات الاحتياطيات، والذي يظهر حجم...
-
DUBAI, United Arab Emirates, March 28, 2024 (GLOBE NEWSWIRE) -- OKX, a leading global Web3 technology company and crypto exchange, today announced the release of its latest Proof of Reserves (PoR)...
-
Defiance ETFs Announces Monthly Distributions on $QQQY (56.94%), $JEPY (37.52%), $IWMY (72.30%), $TRES (11.50%), and $SPYT.
-
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
-
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...